U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07694986) titled 'Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD' on July 06.
Brief Summary: The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), in combination with trastuzumab or nivolumab to confirm the highest dose of the study treatment that can be given safely to participants with Breast Cancer (BC) with Leptomeningeal Disease (LMD).
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Leptomeningeal Disease
Intervention:
BIOLOGICAL: cDC1 Vaccine
Autologous peptide-pulsed cDC1 vaccine administered int...